Skip to content
PICO Portalanswers from OpenAlex

NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

PaperCitations, authors & open-access status

NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma is a paper indexed in PICO Portal from OpenAlex.

How many citations does NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma have?

PICO Portalcitation count

NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma has 123 citations in the OpenAlex counts PICO Portal stores.

When was NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma published?

PICO Portalyear

NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma has 2012 year in the PICO Portal index.

What is the open-access status of NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma?

PICO Portaloa status

NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma has closed oa status in the PICO Portal index.

What is the DOI of NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma?

PICO Portaldoi

The DOI for NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma is on the source record.

What is the PMID of NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma?

PICO Portalpmid

The PMID for NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma is on the source record.

What is the OpenAlex record for NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma?

PICO Portalopenalex

The OpenAlex for NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial